CN1733147A - 一种治疗软组织疼痛的中药制剂及制备方法 - Google Patents
一种治疗软组织疼痛的中药制剂及制备方法 Download PDFInfo
- Publication number
- CN1733147A CN1733147A CN 200510097931 CN200510097931A CN1733147A CN 1733147 A CN1733147 A CN 1733147A CN 200510097931 CN200510097931 CN 200510097931 CN 200510097931 A CN200510097931 A CN 200510097931A CN 1733147 A CN1733147 A CN 1733147A
- Authority
- CN
- China
- Prior art keywords
- parts
- pain
- soft tissue
- daphne giraldii
- giraldii nitsche
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 64
- 210000004872 soft tissue Anatomy 0.000 title claims abstract description 28
- 208000001294 Nociceptive Pain Diseases 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 241001163443 Daphne giraldii Species 0.000 claims abstract description 73
- 239000000284 extract Substances 0.000 claims abstract description 35
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000012530 fluid Substances 0.000 claims abstract description 31
- 229960001047 methyl salicylate Drugs 0.000 claims abstract description 15
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 10
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 8
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims abstract description 8
- 238000011282 treatment Methods 0.000 claims description 38
- 229940079593 drug Drugs 0.000 claims description 20
- 210000000582 semen Anatomy 0.000 claims description 17
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 16
- 239000006071 cream Substances 0.000 claims description 10
- 239000000758 substrate Substances 0.000 claims description 10
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 claims description 8
- 229940057995 liquid paraffin Drugs 0.000 claims description 8
- 229940099259 vaseline Drugs 0.000 claims description 8
- 239000011787 zinc oxide Substances 0.000 claims description 8
- 229940025250 camphora Drugs 0.000 claims description 7
- 239000010238 camphora Substances 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 235000019388 lanolin Nutrition 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 229940098465 tincture Drugs 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 abstract description 95
- 230000000694 effects Effects 0.000 abstract description 91
- 230000036407 pain Effects 0.000 abstract description 91
- 238000006243 chemical reaction Methods 0.000 abstract description 18
- 238000012360 testing method Methods 0.000 abstract description 17
- 239000008280 blood Substances 0.000 abstract description 16
- 210000004369 blood Anatomy 0.000 abstract description 14
- 210000003205 muscle Anatomy 0.000 abstract description 14
- 230000017531 blood circulation Effects 0.000 abstract description 10
- 238000004519 manufacturing process Methods 0.000 abstract description 10
- 230000000144 pharmacologic effect Effects 0.000 abstract description 8
- 230000001737 promoting effect Effects 0.000 abstract description 8
- 238000011160 research Methods 0.000 abstract description 8
- 210000000988 bone and bone Anatomy 0.000 abstract description 6
- 231100000419 toxicity Toxicity 0.000 abstract description 5
- 230000001988 toxicity Effects 0.000 abstract description 5
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 4
- 238000005728 strengthening Methods 0.000 abstract description 4
- 238000010792 warming Methods 0.000 abstract description 4
- 230000008961 swelling Effects 0.000 abstract description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 abstract description 2
- 206010040925 Skin striae Diseases 0.000 abstract description 2
- 208000003455 anaphylaxis Diseases 0.000 abstract description 2
- 239000003960 organic solvent Substances 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 210000002435 tendon Anatomy 0.000 abstract 4
- 230000002040 relaxant effect Effects 0.000 abstract 3
- 230000003213 activating effect Effects 0.000 abstract 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 abstract 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 241001106067 Atropa Species 0.000 abstract 1
- 241000723346 Cinnamomum camphora Species 0.000 abstract 1
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- 229930008380 camphor Natural products 0.000 abstract 1
- 229960000846 camphor Drugs 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 229940041616 menthol Drugs 0.000 abstract 1
- 235000020750 ruta extract Nutrition 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 36
- 230000000202 analgesic effect Effects 0.000 description 17
- 238000000034 method Methods 0.000 description 14
- 230000003110 anti-inflammatory effect Effects 0.000 description 11
- 206010003246 arthritis Diseases 0.000 description 11
- 239000011505 plaster Substances 0.000 description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
- 230000036592 analgesia Effects 0.000 description 9
- ATEFPOUAMCWAQS-UHFFFAOYSA-N 7,8-dihydroxycoumarin Chemical compound C1=CC(=O)OC2=C(O)C(O)=CC=C21 ATEFPOUAMCWAQS-UHFFFAOYSA-N 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- YBGKGTOOPNQOKH-UHFFFAOYSA-N daphnetin Natural products OC1=CC=CC2=C1OC(=O)C=C2O YBGKGTOOPNQOKH-UHFFFAOYSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 201000003068 rheumatic fever Diseases 0.000 description 7
- 206010015150 Erythema Diseases 0.000 description 6
- 206010050031 Muscle strain Diseases 0.000 description 6
- 230000007257 malfunction Effects 0.000 description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 description 6
- 230000035807 sensation Effects 0.000 description 6
- 235000019615 sensations Nutrition 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000010257 thawing Methods 0.000 description 6
- 206010034464 Periarthritis Diseases 0.000 description 5
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 5
- 229940035676 analgesics Drugs 0.000 description 5
- 239000000730 antalgic agent Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 208000036319 cervical spondylosis Diseases 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 208000005801 spondylosis Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 244000153234 Hibiscus abelmoschus Species 0.000 description 3
- 206010023232 Joint swelling Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 208000008765 Sciatica Diseases 0.000 description 3
- 208000007613 Shoulder Pain Diseases 0.000 description 3
- 208000026137 Soft tissue injury Diseases 0.000 description 3
- 208000002240 Tennis Elbow Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 230000001139 anti-pruritic effect Effects 0.000 description 3
- 210000003797 carpal joint Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 229960002895 phenylbutazone Drugs 0.000 description 3
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000000552 rheumatic effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 206010009346 Clonus Diseases 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 241000402754 Erythranthe moschata Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010024453 Ligament sprain Diseases 0.000 description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000010040 Sprains and Strains Diseases 0.000 description 2
- WPUIZWXOSDVQJU-XYPWUTKMSA-N [(1s,5r)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 2-phenylprop-2-enoate Chemical compound C([C@H]1CC[C@@H](C2)N1C)C2OC(=O)C(=C)C1=CC=CC=C1 WPUIZWXOSDVQJU-XYPWUTKMSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003356 anti-rheumatic effect Effects 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 235000019636 bitter flavor Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- HOIXTKAYCMNVMY-PVOAASPHSA-N daphnin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C=CC(=O)O2)C2=C1O HOIXTKAYCMNVMY-PVOAASPHSA-N 0.000 description 2
- HOIXTKAYCMNVMY-UHFFFAOYSA-N daphnin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=CC(=O)O2)C2=C1O HOIXTKAYCMNVMY-UHFFFAOYSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 230000037324 pain perception Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 239000009637 wintergreen oil Substances 0.000 description 2
- RKUNBYITZUJHSG-FXUDXRNXSA-N (S)-atropine Chemical group C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 206010002027 Amyotrophy Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000008037 Arthrogryposis Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 206010005963 Bone formation increased Diseases 0.000 description 1
- 206010007191 Capillary fragility Diseases 0.000 description 1
- 102000009660 Cholinergic Receptors Human genes 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000046691 Daphne odora Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000003153 cholinolytic effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- LGEROVMQYFTBDI-FFIGBMOQSA-N daphnetoxin Chemical compound C1([C@@]23O[C@]4(C[C@H]([C@@]5([C@H]6[C@](C(C(C)=C6)=O)(O)[C@H](O)[C@@]6(CO)O[C@H]6[C@H]5[C@H]4O3)O2)C)C(C)=C)=CC=CC=C1 LGEROVMQYFTBDI-FFIGBMOQSA-N 0.000 description 1
- LGEROVMQYFTBDI-UHFFFAOYSA-N daphnetoxin Natural products O1C2C3C4OC4(CO)C(O)C(C(C(C)=C4)=O)(O)C4C3(O3)C(C)CC2(C(C)=C)OC31C1=CC=CC=C1 LGEROVMQYFTBDI-UHFFFAOYSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- -1 diterpene ortho esters Chemical class 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229930005342 hyoscyamine Natural products 0.000 description 1
- 229960003210 hyoscyamine Drugs 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 206010025005 lumbar spinal stenosis Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 208000010553 multiple abscesses Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 108091008700 nociceptors Proteins 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000004189 reticular formation Anatomy 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000005198 spinal stenosis Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
性别 | 年龄组 | |||
40岁以下(人) | 40-50岁(人) | 50岁以上(人) | 小计(人) | |
男女 | 56 | 1830 | 1520 | 3856 |
合计 | 11 | 48 | 35 | 94 |
分级 | 显效 | 有效 | 无效 | 总有效者 |
例数% | 8489.4 | 99.57 | 11.06 | 9298.97 |
性别 | 年龄分组(岁) | ||||||||
男 | 女 | <21 | 21~30 | 31~40 | 41~50 | 51~60 | >60 | 总计 | |
例数 | 173 | 229 | 2 | 49 | 59 | 137 | 113 | 42 | 402 |
疗效分级 | 显效 | 有效 | 无效 | 合计 | |||
数 | % | 数 | % | 数 | % | 数量 | |
例数 | 170 | 42.29 | 208 | 51.74 | 24 | 5.97 | 402 |
复方祖司麻止痛膏 | 祖司麻关节止痛膏 | ||||||
例数 | 平均值 | 标准值 | 例数 | 平均值 | 标准值 | ||
起效时间(分) | 60 | 16.2 | 23.12 | 60 | 28.7 | 26.06 | T=2.417 |
维持时间(小时) | 60 | 29.35 | 19.1 | 60 | 21.75 | 18.2 | T=3.3456 |
样品 | 浓度 | 菌株生长情况 | |||
金葡 | 大肠 | 绿脓 | 福氏 | ||
祖司麻甲素祖司麻甲素祖司麻甲素祖司麻甲素祖司麻甲素祖司麻乙素祖司麻乙素祖司麻乙素空白 | 1∶100002∶100005∶1000010∶1000020∶1000020∶100005∶1000010∶10000 | -----++--+++ | +++-±--+++--+++ | ++++---+++--+++ | ++----+++--+++ |
药物名称 | 试验部值数 | 皮肤反应 | |||||
严重反应 | 轻度反应 | 无反应 | |||||
部位数 | % | 部位数 | % | 部位数 | % | ||
复方祖司麻止痛膏 | 24 | 0 | 4 | 16.7 | 20 | 83.3 | |
祖师麻关节止痛膏 | 24 | 4 | 16.7 | 8 | 33.3 | 12 | 50 |
共计 | 48 | 4 | 12 | 32 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100979319A CN100348239C (zh) | 2005-09-01 | 2005-09-01 | 一种治疗软组织疼痛的中药制剂及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100979319A CN100348239C (zh) | 2005-09-01 | 2005-09-01 | 一种治疗软组织疼痛的中药制剂及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1733147A true CN1733147A (zh) | 2006-02-15 |
CN100348239C CN100348239C (zh) | 2007-11-14 |
Family
ID=36075902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100979319A Active CN100348239C (zh) | 2005-09-01 | 2005-09-01 | 一种治疗软组织疼痛的中药制剂及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100348239C (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101444574B (zh) * | 2008-12-31 | 2011-03-30 | 赵东科 | 一种祖司麻流浸膏的制备及质量检测方法 |
CN104888113A (zh) * | 2015-05-27 | 2015-09-09 | 神威药业集团(山东)有限公司 | 一种活血化瘀、和络止痛的按摩软膏及其制备方法 |
CN111450174A (zh) * | 2020-04-28 | 2020-07-28 | 甘肃祖师麻制药有限公司 | 祖师麻关节止痛膏的生产工艺 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1362199A (zh) * | 2001-01-02 | 2002-08-07 | 杨孟君 | 一种纳米祖师麻制剂药物及其制备方法 |
CN1365783A (zh) * | 2001-01-19 | 2002-08-28 | 杨孟君 | 纳米伤湿止痛制剂药物及其制备方法 |
-
2005
- 2005-09-01 CN CNB2005100979319A patent/CN100348239C/zh active Active
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101444574B (zh) * | 2008-12-31 | 2011-03-30 | 赵东科 | 一种祖司麻流浸膏的制备及质量检测方法 |
CN104888113A (zh) * | 2015-05-27 | 2015-09-09 | 神威药业集团(山东)有限公司 | 一种活血化瘀、和络止痛的按摩软膏及其制备方法 |
CN104888113B (zh) * | 2015-05-27 | 2018-05-01 | 神威药业集团(山东)有限公司 | 一种活血化瘀、和络止痛的按摩软膏及其制备方法 |
CN111450174A (zh) * | 2020-04-28 | 2020-07-28 | 甘肃祖师麻制药有限公司 | 祖师麻关节止痛膏的生产工艺 |
Also Published As
Publication number | Publication date |
---|---|
CN100348239C (zh) | 2007-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1872235A (zh) | 麝香追风止痛膏及其制备方法 | |
CN1319569C (zh) | 治疗骨质疏松及骨折的中药制剂及其制备方法 | |
CN101757117A (zh) | 一种中草药调理剂及其制备方法 | |
CN101007040B (zh) | 治疗骨折的外用药物 | |
CN1733147A (zh) | 一种治疗软组织疼痛的中药制剂及制备方法 | |
CN101829182B (zh) | 一种治疗前列腺疾病的药物 | |
CN1843441A (zh) | 除痹通络外敷贴 | |
CN1663599A (zh) | 治疗风湿性、类风湿性疾病的狗皮膏(改进型)及其制备方法 | |
CN1823912A (zh) | 一种消炎药物 | |
CN101940652B (zh) | 治疗牛皮癣、各种顽癣、瘙痒症的中药擦剂 | |
CN1899490A (zh) | 一种治疗气滞血淤型的急、慢性软组织损伤的搽剂及其制备方法 | |
CN1108166C (zh) | 消炎止痛剂 | |
CN103638232B (zh) | 一种治疗风湿病的中药组合物 | |
Axe et al. | The Essential Oils Home Remedy Guide | |
CN102000166B (zh) | 一种治疗风湿性关节炎和类风湿性关节炎的药酒 | |
CN101530448A (zh) | 一种治疗跌打损伤的外用中药贴膏 | |
CN100420466C (zh) | 一种豆瓣绿跌打药酒 | |
CN1248723C (zh) | 一种治疗痹症的药液和制备方法 | |
CN1739711A (zh) | 一种红景天外用药 | |
CN105456648A (zh) | 一种复方五藤消痛贴 | |
CN102743449A (zh) | 一种治疗鹅口疮的散剂药物 | |
CN1331981A (zh) | 跌打镇痛药 | |
CN1184981C (zh) | 一种止痛擦剂 | |
CN1166392C (zh) | 止痛膏 | |
CN101822699B (zh) | 一种治疗牛皮癣的中药及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: YANGLING DONGKE MAIDISEN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHAO DONGKE Effective date: 20100617 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 712100 NO.8, XINQIAO ROAD, YANGLING DEMONSTRATION ZONE, SHANXI PROVINCE TO:710043 4/F, DONGXINGKEJI BUILDING, XINCHENG SCI-TECH INDUSTRY PARK, NO.1, XINKE ROAD, XI AN CITY, SHANXI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100617 Address after: 710043 4 floor, Dongxing science and technology building, Xincheng science and Technology Industrial Park, No. 1, Xinke Road, Shaanxi, Xi'an Patentee after: Dongke Maidisen Pharmaceutical Co., Ltd., Yangling Address before: 712100 No. 8 Xinqiao Road, Yangling demonstration area, Shaanxi Patentee before: Zhao Dongke |
|
ASS | Succession or assignment of patent right |
Owner name: SHAANXI DONGKE PHARMACEUTICAL LLC Free format text: FORMER OWNER: DONGKE MAIDISEN PHARMACEUTICAL CO., LTD., YANGLING Effective date: 20150106 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 710043 XI AN, SHAANXI PROVINCE TO: 712100 XIANYANG, SHAANXI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150106 Address after: 712100 No. 8 Xinqiao Road, Yangling demonstration area, Shaanxi Patentee after: SHAANXI DONGKE PHARMACEUTICAL CO., LTD. Address before: 710043 4 floor, Dongxing science and technology building, Xincheng science and Technology Industrial Park, No. 1, Xinke Road, Shaanxi, Xi'an Patentee before: Dongke Maidisen Pharmaceutical Co., Ltd., Yangling |